Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.
Fu J et al. J Clin Invest. 2016 Apr 4. pii: 80276. doi: 10.1172/JCI80276. [Epub ahead of print].
Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.
Bieghs L et al. PLoS One. 2016 Apr 25;11(4):e0154256. doi: 10.1371/journal.pone.0154256. eCollection 2016.
Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma.
Wuillème S et al. Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.74. [Epub ahead of print].
Cadherin-11 (CDH11) expression in the peripheral blood of patients with active Multiple Myeloma.
Christopoulos PF et al. Br J Haematol. 2016 Apr 26. doi: 10.1111/bjh.14105. [Epub ahead of print].
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
Shah MY et al. Oncogene. 2016 Apr 25. doi: 10.1038/onc.2016.116. [Epub ahead of print].
3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
Lei M et al. Bioorg Med Chem. 2016 Apr 13. pii: S0968-0896(16)30259-0. doi: 10.1016/j.bmc.2016.04.025. [Epub ahead of print].
Multiple myeloma causes clonal T cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.
Suen H et al. Leukemia. 2016 Apr 22. doi: 10.1038/leu.2016.84. [Epub ahead of print].
Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.
De Veirman K et al. Cancer Lett. 2016 Apr 19. pii: S0304-3835(16)30259-2. doi: 10.1016/j.canlet.2016.04.024. [Epub ahead of print].
Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN et al. Clin Lymphoma Myeloma Leuk. 2016 Mar 29. pii: S2152-2650(16)30018-0. doi: 10.1016/j.clml.2016.03.006. [Epub ahead of print].
Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S et al. Curr Opin Hematol. 2016 Apr 20. [Epub ahead of print].
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Ray A et al. Br J Haematol. 2016 Apr 20. doi: 10.1111/bjh.14065. [Epub ahead of print].
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors.
Cee VJ et al. ACS Med Chem Lett. 2016 Feb 12;7(4):408-12. doi: 10.1021/acsmedchemlett.5b00403. eCollection 2016.
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R et al. Oncotarget. 2016 Apr 15. doi: 10.18632/oncotarget.8750. [Epub ahead of print].
Expression Profile Of The Individual Genes Corresponding To The Genes Generated By The Cytotoxicity Experiments Of Bortezomib In Multiple Myeloma.
Ghasemi M et al. Turk J Haematol. 2016 Apr 18. doi: 10.4274/tjh.2015.0145. [Epub ahead of print].
miR-320a regulates cell proliferation and apoptosis in multiple myeloma by targeting pre-B-cell leukemia transcription factor 3.
Lu Y et al. Biochem Biophys Res Commun. 2016 Apr 14. pii: S0006-291X(16)30571-X. doi: 10.1016/j.bbrc.2016.04.069. [Epub ahead of print].
Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
Canitano A et al. Cancer Lett. 2016 Apr 12. pii: S0304-3835(16)30250-6. doi: 10.1016/j.canlet.2016.04.015. [Epub ahead of print].
Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma.
Konjević G et al. J Clin Pathol. 2016 Apr 15. pii: jclinpath-2016-203614. doi: 10.1136/jclinpath-2016-203614. [Epub ahead of print].
Newly established myeloma-derived stromal cell line MSP-1 supports Multiple Myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.
de la Puente P et al. Haematologica. 2016 Apr 14. pii: haematol.2016.142190. [Epub ahead of print].
Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice.
Lee DU et al. Toxicol Appl Pharmacol. 2016 Apr 11;300:47-54. doi: 10.1016/j.taap.2016.03.013. [Epub ahead of print].
Involvement of the arachidonic acid cytochrome P450 epoxygenase pathway in the proliferation and invasion of human multiple myeloma cells.
Shao J et al. Peer J. 2016 Apr 11;4:e1925. doi: 10.7717/peerj.1925. eCollection 2016.
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with Multiple Myeloma and different prognosis.
Martello M et al. Leukemia. 2016 Apr 14. doi: 10.1038/leu.2016.77. [Epub ahead of print].
Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context.
Segges P et al. Braz J Med Biol Res. 2016;49(5):e5034. doi: 10.1590/1414-431X20155034. Epub 2016 Apr 8.
Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94.
Ansa-Addo EA et al. Curr Top Med Chem. 2016 Apr 13. [Epub ahead of print].
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Lee SJ et al. Br J Haematol. 2016 Apr 12. doi: 10.1111/bjh.14014. [Epub ahead of print].
The effects of cold atmospheric plasma on cell adhesion, differentiation, migration, apoptosis and drug sensitivity of multiple myeloma.
Xu D et al. Biochem Biophys Res Commun. 2016 Apr 8. pii: S0006-291X(16)30522-8. doi: 10.1016/j.bbrc.2016.04.027. [Epub ahead of print].
A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients.
Magrangeas F et al.Clin Cancer Res. 2016 Apr 8. pii: clincanres.3163.2015. [Epub ahead of print].
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
Kowalewski DJ et al. Blood Cancer J. 2016 Apr 8;6:e411. doi: 10.1038/bcj.2016.14.
Differential effects of lenalidomide during plasma cell differentiation.
Jourdan M et al. Oncotarget. 2016 Apr 4. doi: 10.18632/oncotarget.8581. [Epub ahead of print].
Heparanase and cancer progression: New directions, new promises.
Arvatz G et al. Hum Vaccin Immunother. 2016 Apr 7:1-4. [Epub ahead of print].
Human platelets repurposed as vehicles for in vivo imaging of myeloma xenotransplants.
Dai L et al. Oncotarget. 2016 Mar 31. doi: 10.18632/oncotarget.8517. [Epub ahead of print].
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Deng J et al. Oncotarget. 2016 Mar 31. doi: 10.18632/oncotarget.8513. [Epub ahead of print].
Dual inhibition of oncogenic targets for B-cell malignancies.
Richardson PG. Lancet Oncol. 2016 Mar 31. pii: S1470-2045(16)00109-1. doi: 10.1016/S1470-2045(16)00109-1. [Epub ahead of print].
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.
Song Y et al.Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.97. [Epub ahead of print].
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes in particular in redox and energy metabolism.
Soriano GP et al. Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.102. [Epub ahead of print].
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance inmultiple myeloma cells.
Das DS et al. Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.96. [Epub ahead of print].
Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E et al. Oncogene. 2016 Apr 4. doi: 10.1038/onc.2016.86. [Epub ahead of print].
A transplant immunome deep sequencing and screening platform defines a unique targetable epitope fingerprint of multiple myeloma.
Schieferdecker A et al. Blood. 2016 Mar 31. pii: blood-2015-10-676536. [Epub ahead of print].
Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
Hermansen NE et al. Int J Lab Hematol. 2016 Mar 29. doi: 10.1111/ijlh.12486. [Epub ahead of print].
Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma.
Amodio N et al. Mol Cancer Ther. 2016 Mar 28. pii: molcanther.0985.2015. [Epub ahead of print].